Crossmark

Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review

Published Online: 2021-07-26

Published Print: 2022-09

Authors

Huang, Peixin https://orcid.org/0000-0003-4358-3798
Zhou, Yingting https://orcid.org/0000-0001-5188-7594
Chen, Yi https://orcid.org/0000-0002-9675-5998
License Information

Text and Data Mining valid from 2021-07-26

Version of Record valid from 2021-07-26
More Information

Article History

Accepted: 11 April 2021

First Online: 26 July 2021

Declarations

:

: The study was approved by the Clinical Research Ethics Committee of Fudan University Affiliated Zhongshan Hospital.

: Informed, written consent was obtained from the patient for publication of this case report and accompanying images.

Document is current